Immunotherapy Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Immunotherapy stocks.

Immunotherapy Stocks Recent News

Date Stock Title
Nov 22 APTO S&P 500 Moves Higher; Intuit Shares Fall Following Q1 Results
Nov 22 APTO Aptose Biosciences to sell 40M shares at $0.20 in public offering
Nov 22 APTO Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering
Nov 22 NKTX Nkarta price target lowered to $16 from $20 at Mizuho
Nov 21 LCTX Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering
Nov 21 LCTX Lineage Cell (LCTX) Loses -26.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Nov 21 ALBT Avalon Globocare regains Nasdaq compliance
Nov 21 ALBT Avalon GloboCare Regains Compliance with Nasdaq Continued Listing Requirements
Nov 20 LCTX Lineage Cell Therapeutics tumbles after pricing $66M securities offering
Nov 20 LCTX Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering
Nov 20 APTO Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy
Nov 20 IMTX Immatics N.V. (NASDAQ:IMTX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Nov 19 IMTX Immatics Sees Revenue Surge Despite R&D Expenses
Nov 19 ADTX Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.
Nov 18 EVAX Evaxion Biotech files for offering of ADSs
Nov 18 ALBT (ALBT) - Analyzing Avalon Globocare's Short Interest
Nov 18 ALBT Avalon GloboCare Launches “BrAce for Impact" Affiliate Marketing Program for the KetoAir Breathalyzer Device
Nov 18 IMTX Immatics GAAP EPS of -€0.11, revenue of €50.56M
Nov 18 IMTX Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME
Immunotherapy

Immunotherapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies.

In recent years, immunotherapy has become of great interest to researchers, clinicians and pharmaceutical companies, particularly in its promise to treat various forms of cancer.Immunomodulatory regimens often have fewer side effects than existing drugs, including less potential for creating resistance when treating microbial disease.Cell-based immunotherapies are effective for some cancers. Immune effector cells such as lymphocytes, macrophages, dendritic cells, natural killer cells (NK Cell), cytotoxic T lymphocytes (CTL), etc., work together to defend the body against cancer by targeting abnormal antigens expressed on the surface of tumor cells.
Therapies such as granulocyte colony-stimulating factor (G-CSF), interferons, imiquimod and cellular membrane fractions from bacteria are licensed for medical use. Others including IL-2, IL-7, IL-12, various chemokines, synthetic cytosine phosphate-guanosine (CpG) oligodeoxynucleotides and glucans are involved in clinical and preclinical studies.

Browse All Tags